TY - JOUR
T1 - Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases
AU - Ter Haar, Nienke M.
AU - Eijkelboom, Charlotte
AU - Cantarini, Luca
AU - Papa, Riccardo
AU - Brogan, Paul A.
AU - Kone-Paut, Isabelle
AU - Modesto, Consuelo
AU - Hofer, Michael
AU - Iagaru, Nicolae
AU - Fingerhutová, Sárka
AU - Insalaco, Antonella
AU - Licciardi, Francesco
AU - Uziel, Yosef
AU - Jelusic, Marija
AU - Nikishina, Irina
AU - Nielsen, Susan
AU - Papadopoulou-Alataki, Efimia
AU - Olivieri, Alma Nunzia
AU - Cimaz, Rolando
AU - Susic, Gordana
AU - Stanevica, Valda
AU - Van Gijn, Marielle
AU - Vitale, Antonio
AU - Ruperto, Nicolino
AU - Frenkel, Joost
AU - Gattorno, Marco
N1 - Funding Information:
Funding The project has been supported by the executive agency For Health and Consumers (eaHC, Project no. 2007332) and e-rare-3 project (insaiD, grant 003037603). novartis and sOBi provided unrestricted grants for the eurofever registry.
Funding Information:
The project has been supported by the Executive Agency For Health and Consumers (EAHC, Project No. 2007332) and E-rare-3 project (INSAID, grant 003037603). Novartis and SOBI provided unrestricted grants for the Eurofever registry.
Publisher Copyright:
© © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2019
Y1 - 2019
N2 - Objectives To describe the clinical characteristics, treatment response and genetic findings in a large cohort of patients with undefined systemic autoinflammatory diseases (SAIDs). Methods Clinical and genetic data from patients with undefined SAIDs were extracted from the Eurofever registry, an international web-based registry that retrospectively collects clinical information on patients with autoinflammatory diseases. Results This study included 187 patients. Seven patients had a chronic disease course, 180 patients had a recurrent disease course. The median age at disease onset was 4.3 years. Patients had a median of 12 episodes per year, with a median duration of 4 days. Most commonly reported symptoms were arthralgia (n=113), myalgia (n=86), abdominal pain (n=89), fatigue (n=111), malaise (n=104) and mucocutaneous manifestations (n=128). In 24 patients, relatives were affected as well. In 15 patients, genetic variants were found in autoinflammatory genes. Patients with genetic variants more often had affected relatives compared with patients without genetic variants (p=0.005). Most patients responded well to non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, colchicine and anakinra. Complete remission was rarely achieved with NSAIDs alone. Notable patterns were found in patients with distinctive symptoms. Patients with pericarditis (n=11) were older at disease onset (33.8 years) and had fewer episodes per year (3.0/year) compared with other patients. Patients with an intellectual impairment (n=8) were younger at disease onset (2.2 years) and often had relatives affected (28.6%). Conclusion This study describes the clinical characteristics of a large cohort of patients with undefined SAIDs. Among these, patients with pericarditis and intellectual impairment appear to comprise distinct subsets.
AB - Objectives To describe the clinical characteristics, treatment response and genetic findings in a large cohort of patients with undefined systemic autoinflammatory diseases (SAIDs). Methods Clinical and genetic data from patients with undefined SAIDs were extracted from the Eurofever registry, an international web-based registry that retrospectively collects clinical information on patients with autoinflammatory diseases. Results This study included 187 patients. Seven patients had a chronic disease course, 180 patients had a recurrent disease course. The median age at disease onset was 4.3 years. Patients had a median of 12 episodes per year, with a median duration of 4 days. Most commonly reported symptoms were arthralgia (n=113), myalgia (n=86), abdominal pain (n=89), fatigue (n=111), malaise (n=104) and mucocutaneous manifestations (n=128). In 24 patients, relatives were affected as well. In 15 patients, genetic variants were found in autoinflammatory genes. Patients with genetic variants more often had affected relatives compared with patients without genetic variants (p=0.005). Most patients responded well to non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, colchicine and anakinra. Complete remission was rarely achieved with NSAIDs alone. Notable patterns were found in patients with distinctive symptoms. Patients with pericarditis (n=11) were older at disease onset (33.8 years) and had fewer episodes per year (3.0/year) compared with other patients. Patients with an intellectual impairment (n=8) were younger at disease onset (2.2 years) and often had relatives affected (28.6%). Conclusion This study describes the clinical characteristics of a large cohort of patients with undefined SAIDs. Among these, patients with pericarditis and intellectual impairment appear to comprise distinct subsets.
KW - autoinflammatory diseases
KW - eurofever
KW - inflammation
KW - recurrent fever
UR - http://www.scopus.com/inward/record.url?scp=85068611687&partnerID=8YFLogxK
U2 - 10.1136/annrheumdis-2018-214472
DO - 10.1136/annrheumdis-2018-214472
M3 - Article
C2 - 31278138
AN - SCOPUS:85068611687
SN - 0003-4967
VL - 78
SP - 1405
EP - 1411
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
IS - 10
ER -